Skip to main content
RTW Biotech Opportunities Ltd logo

RTW Biotech Opportunities Ltd — Investor Relations & Filings

Ticker · RTW ISIN · GG00BKTRRM22 LEI · 549300Q7EXQQH6KF7Z84 IL Financial and insurance activities
Open in API
Filings indexed 545 across all filing types
Latest filing 2026-01-15 Net Asset Value
Country GG Guernsey
Listing IL RTW

About RTW Biotech Opportunities Ltd

https://www.rtwfunds.com/rtw-biotech-op…

RTW Biotech Opportunities Ltd is an investment fund that focuses on identifying and investing in transformative assets with high growth potential across the global life sciences sector. The company's portfolio is primarily composed of biotechnology and medical technology companies. Managed by RTW Investments, LP, a specialized life sciences investment firm, the fund leverages deep scientific expertise to support companies throughout their entire lifecycle, from early-stage private ventures to publicly traded entities. The investment strategy aims to provide capital and strategic support to advance the development of innovative therapies and technologies.

Recent filings

Filing Released Lang Actions
Monthly Valuation Update and Factsheet
Net Asset Value Classification · 95% confidence The document is an RNS (Regulatory News Service) announcement from RTW Biotech Opportunities Ltd. It provides a monthly valuation update, including the Net Asset Value (NAV) per share, performance metrics, top positions, and a market commentary. While it mentions that a factsheet is available via a link, the document itself contains the core financial data (NAV, performance, portfolio updates) and is not merely a notification of a report's existence. Given the focus on NAV and fund performance, it is classified as a Net Asset Value (NAV) update.
2026-01-15 English
Aktis announces $318 million IPO
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from the London Stock Exchange. It reports on a portfolio company's (Aktis Oncology) IPO and its impact on the reporting company's (RTW Biotech Opportunities Ltd) NAV. Since it is a general regulatory announcement regarding company news that does not fit into specific categories like financial reports or shareholder voting, it is classified as a Regulatory Filing (RNS).
2026-01-12 English
Total Voting Rights
Regulatory Filings Classification · 100% confidence The document is a regulatory announcement regarding 'Total Voting Rights' issued in accordance with DTR 5.6.1 of the FCA's Disclosure Guidance and Transparency Rules. It provides the total number of voting rights for shareholders to use as a denominator for notification requirements. This type of disclosure is a standard regulatory filing required by the London Stock Exchange (RNS) and does not fit into specific categories like dividends, M&A, or financial reports. Therefore, it is classified as a Regulatory Filing (RNS).
2026-01-02 English
New investment in Yarrow Bioscience
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from the London Stock Exchange regarding a new investment by RTW Biotech Opportunities Ltd in Yarrow Bioscience. While the document discusses a merger (M&A activity), it is primarily an announcement of a capital investment and strategic partnership. Given the document's format as a regulatory news release and its focus on corporate activity, it fits best under the 'RNS' category, which serves as the standard for regulatory announcements of this nature.
2025-12-18 English
Monthly Valuation Update and Factsheet
Net Asset Value Classification · 95% confidence The document is a monthly update from RTW Biotech Opportunities Ltd, which is an investment fund. It explicitly provides the monthly Net Asset Value (NAV) per share, performance metrics, and a breakdown of top positions. While it mentions that a factsheet is available via a link, the document itself contains the core financial data (NAV, performance, portfolio holdings) and management commentary, making it a primary NAV update filing rather than just a report publication announcement.
2025-12-12 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from RTW Biotech Opportunities Ltd regarding the repurchase of 250,000 of its own ordinary shares to be held in treasury. The text explicitly mentions 'Transaction in Own Shares' as the subject and provides details on the number of shares, price, and the impact on total voting rights. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-12-10 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.